Table 4.
Novel radiolabeled small-molecule binders.
| Agent | Type of radiation | NCT number | Clinical trial phase | Location | Primary outcome measure |
|---|---|---|---|---|---|
| 225Ac-PSMA-617 | Alpha | NCT04597411 | 1 | International | R2PD |
| I-131-1095 | Beta | NCT03939689 | 2 | International | PSA response |
| 177Lu-DOTA-N3-CTT1403 | Beta | NCT03822871 | 1 | United States | DLT |
| 177Lu-PSMA-R2 | Beta | NCT03490838 | 1 | International | DLT PSA response |
| PSMA Cu-64/67 trial | Beta | NCT04868604 | 1/2 | United States | Safety Tolerability Efficacy |
Abbreviations: DLT, dose-limiting toxicity; RP2D, recommended phase II dose.